Buy Tecentriq (Atezolizumab). Tecentriq (atezolizumab) is a drug that blocks a protein called PD-L1. It is used to treat several types of cancer. These include:
locally advanced or metastatic urothelial carcinoma who have either; disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy[1] or are not eligible for cisplatin chemotherapy.
metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy.
plus nab-paclitaxel (chemotherapy) for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression.
How does Tecentriq (atezolizumab) work?
Tecentriq (atezolizumab) is an immunotherapy drug. It works by stopping a protein called PD-L1 from binding to PD-1 on immune cells. This action suppresses the immune response.
By blocking this interaction, Tecentriq (atezolizumab) “releases the brakes” on the immune system. This lets immune cells attack tumours.
Is Tecentriq (atezolizumab) approved?
Tecentriq (atezolizumab) has been approved by several organizations. These include:
Food and Drugs Administration (FDA) (USA)
on May 18, 2016, for locally advanced or metastatic urothelial carcinoma, with disease progression on or after prior chemotherapy. On April 17, 2017, the FDA extended the approval to the use of Tecentriq (atezolizumab) as front-line treatment for advanced or metastatic urothelial carcinoma in patients who are not eligible for cisplatin chemotherapy.
on October 18, 2016, for metastatic non-small cell lung cancer (NSCLC).
Health Canada on April 12, 2017
for locally advanced or metastatic urothelial carcinoma, with disease progression on or after prior chemotherapy.
for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide.
for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with bevacizumab, paclitaxel and carboplatin.
for adult patients with locally advanced or metastatic NSCLC with progression on or after platinum-based chemotherapy.
Therapeutic Goods Administration (TGA) (AUS)
on July 27, 2017, for metastatic non-small cell lung cancer (NSCLC).
What is Tecentriq (atezolizumab) used for?
European Medicines Agency (EMA) (EU)
on September 22, 2017, for locally advanced or metastatic non-small cell cancer (NSCLC) and metastatic urothelial carcinoma (mUC) on patients who have been previously treated with a platinum-based chemotherapy and as front-line treatment for advanced or metastatic urothelial carcinoma in patients who are not eligible for cisplatin chemotherapy.
on August 29, 2019, in combination with nab-paclitaxel for advanced TNBC in patients who have not been previously treated with chemotherapy for metastatic disease.
Medsafe on February 14, 2019
for first-line treatment of patients with metastatic non-squamous NSCLC who do not have tumour EGFR or ALK genomic aberrations.
for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.
for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.
How do I take Tecentriq (atezolizumab)?
For full details on Tecentriq (atezolizumab) dosage and administration, see the references section.
The recommended therapy is:
1200 mg as an intravenous infusion over 60 minutes every 3 weeks.
Dilute prior to intravenous infusion.
For more information on Tecentriq (atezolizumab) dosage and administration, see the references section.
Consult your treating doctor for personalised dosing.
Are there any known side effects of Tecentriq (atezolizumab)?
In patients with locally advanced or metastatic urothelial carcinoma, common side effects included fatigue, decreased appetite, and nausea. Other common side effects were constipation, urinary tract infections, diarrhea, and fever. For patients with metastatic non-small cell lung cancer, common side effects were fatigue, decreased appetite, and dyspnea. Other common side effects included cough, nausea, musculoskeletal pain, and constipation.
Optimized by Seraphinite Accelerator